LIQ861 is an investigational, inhaled dry powder formulation of treprostinil delivered through a device, which currently has tentative approval from the FDA for the treatment of pulmonary arterial hypertension (PAH). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) about LIQ861 and its potential advantages over conventional formulations of treprostinil in PAH.
The abstract ‘GREATER CLINICAL BENEFITS FROM HIGHER DOSES OF INHALED LIQ861 THAN LOWER DOSES: EXPLORATORY EFFICACY ANALYSES FROM THE LTI-301 CLINICAL TRIAL.’ (Poster 2081) was presented at CHEST 2022, 16-19 October, 2022.
Questions
- What are the limitations of treprostinil in the treatment of patients with pulmonary arterial hypertension (PAH)? (0:13)
- Could you tell us a little about LIQ861 and its potential advantages over conventional formulations of treprostinil in PAH? (1:22)
Disclosures: Marc Simon discloses consulting for ImpulseDynamics and serving on advisory boards for Acceleron, Aerovate, Janssen, and Liquidia.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the CHEST meeting 2022.
